In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Merus (MRUS – Research Report), with a price ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

Despite the PDUFA date being extended by three months for Merus’ zenocutuzumab, Truist Securities analyst Asthika ...

Merus on Tuesday said the Food and Drug Administration extended its review of the clinical-stage oncology company's proposed zenocutuzumab cancer treatment.

The FDA has scuttled Merus’ plans to win a speedy approval for i | The FDA has scuttled Merus’ plans to win a speedy approval ...

Andrew Berens, an analyst from Leerink Partners, maintained the Buy rating on Merus (MRUS – Research Report). The associated price target ...

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Merus (NASDAQ:MRUS – Free Report) by 24.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 2,467 shares of ...

Team Rebounds: 6. Team Turnovers: None. Blocked Shots: 4 (Crujeiras, Martin, Potter, Whalen). Turnovers: 19 (Whalen 4, Aubry-Thomas 3, Hagan 3, Mugosa 2, Potter 2, Williams 2, Hansen, Martin, Zapater) ...

Hagan 1-4 0-0 2, Zapater 0-1 0-0 0, Mugosa 1-3 0-0 3, Potter 2-5 2-3 6, Williams 3-6 1-3 9, Whalen 1-2 0-0 2, Martin 5-9 0-0 12, Aubry-Thomas 0-6 2-2 2, Hansen 1-2 3-6 5, Wilson 3-5 0-0 7, ...

Idaho – which finished 11-21, with a 5-13 mark in the Big Sky – won half of its preseason games before coming up with some ...

Merus N.V. (MRUS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.43 per share a year ago. These figures are ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical ...